Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Two-sample FIT-screening: a 4th screening round

ABSTRACT: Interventions: People will receive two identical FITs (OC-sensor, Eiken Japan) to sample from two consecutive bowel movements. Primary outcome(s): Participation, positivity rate, diagnostic yield of two-sample FIT screening. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Parallel

DISEASE(S): Colorectal Cancer, Screening, Darmkanker

PROVIDER: 19798 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Comparison study of two fecal immunochemical tests within a nationwide colorectal cancer screening program

Project description:Interventions: Screenees will receive two FITs (OC-sensor, Eiken Japan and FOB-Gold, Sentinel) to sample from one bowel movement. Primary outcome(s): detection rate of advanced neoplasia Study Design: N/A: single arm study, Single blinded (masking used), Active, Parallel

| 20104 | ecrin-mdr-crc

Various aspects of FIT-screening: a 4th screening round.

Project description:Interventions: n.a. Primary outcome(s): Participation, positivity rate, diagnostic yield and practical use for two types of FITs (OC-Sensor and FOB-Gold) Study Design: Randomized controlled trial, Open (masking not used), N/A , unknown, Parallel

| 19664 | ecrin-mdr-crc

Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening

Project description:Colorectal cancer screening by faecal occult blood test (FOBT) is a high public health priority. The interest of guaiac tests (G-FOBT) is limited by their poor sensitivity, while the superiority of I-FOBT in comparison with G-FOBT is now established. Nevertheless automated quantitative I-FOBTs have not been compared, and the optimal number of samples and threshold is not yet fixed. The aim of this study is to compare the performances of the 2 more well-known I-FOBTs with automated analyzers (magstream by Fujirebio, and OC Sensor by Eiken) for different positivity thresholds and numbers of samples in general average risk population. Patients will performed a two samples Magstream, a two samples OC Sensor and Hemoccult II. In case of a positive test, a colonoscopy will be performed. Sensitivity and specificity for detection of cancer and advanced neoplasias will be compared between tests using ratio of sensitivities (RSN) and ratio of false positives (RFP) according to number of samples and positivity threshold.

| 2098890 | ecrin-mdr-crc

Diagnostic sensitivity analysis of the immunochemical fecal occult blood test for colorectal cancers

Project description:Interventions: Immunochemical fecal occult blood test (FIT) using OC sensor io (Eiken co) Primary outcome(s): Diagnostic sensitivity of immunochemical fecal occult blood test (FIT) for colorectal cancers based on the location, staging, tumor size and macroscopic types. Study Design: Single arm Non-randomized

| 2624966 | ecrin-mdr-crc

Immunochemical FOBT screening for colorectal cancer: yield and attendance for one- versus two-sample tests, and for second round screening with various intervals.

Project description:Interventions: 1-sample or 2-samples immunochemical FOBTs. Firstly, a representative population sample of 2.500 asymptomatic persons between 50-75 years of age in the region ‘Rijnmond’ will be invited for the 1st screening round using 1-sample iFOBT in 2008 and for a 2nd screening round after one year (group A). Secondly, the 5.000 asymptomatic persons who were invited in our first trial for a 1st-round one-sample iFOBT in 2006/2007 (NTR = 1096), will be invited for 2nd round screening. They will be pre-randomized for biennial (group B) or triennial (group C) 2nd round screening. The attendance rate of these two groups will be compared with the participation of the second screening round from group A. Furthermore, 3.200 newly randomly selected persons will be invited for a single 1st round screening using 2-sample iFOBT (group D). The attendance rate of this group will be compared with the participation of the first screening round from group A. Primary outcome(s): Adherence for second round CRC screening with 1-sample iFOBT (OC-Hemodia Latex) comparing annual, biennial, and triennial screening interval. Adherence and diagnostic yield of a first screening round comparing 1-sample versus 2-sample iFOBT screening. Study Design: Randomized controlled trial, Open (masking not used), N/A , unknown, Parallel

| 15872 | ecrin-mdr-crc

Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy

Project description:Aims: 1. To compare the efficacy of biennial immunochemical fecal occult blood test (iFOBT) versus colonoscopy every 10 years for the reduction of colorectal cancer-related mortality at 10 years in average-risk population. 2. To determine the compliance and complications associated with both strategies. Methods: Multicenter, randomized, controlled study in 8 Spanish regions (Aragón, Canarias, Catalunya, Euskadi, Galicia, Madrid, Murcia and Valencia). Study groups: * Group I: iFOBT (OC Sensor) in one stool sample, followed by colonoscopy when a positive result. * Group II: colonoscopy. Sample-size calculation: 27,749 subjects in each study group (total: 55,498).

| 2072705 | ecrin-mdr-crc

Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): 3 round.

Project description:Interventions: For this study, 10.000 individuals will be invited for CRC screening by FIT (OC-sensor). Primary outcome(s): Participation rate. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Parallel

| 17029 | ecrin-mdr-crc

Assessing the impact of a new fit test in the context of a population based organized screening programme for colorectal cancer

Project description:Background and study aims Colorectal, or bowel cancer, is very common. However, if detected at an early stage, it can be easier to treat and led to a much better chance of survival. The fecal immunochemical test (FIT) is a screening test for bowel cancer that tests for hidden blood in the stool. Blood in the stool can be an early sign of the disease. This study is investigating a new FIT screening test called FIT HM-Jackarc. It compares how this test performs against the test that is in routine use (FIT OC-Sensor Diana). Who can participate? Adults aged between 50-75. What does the study involve? Participants are randomly allocated to one of two groups. One group is screened for colorectal cancer using FIT HM-Jackarc. The other group is screened for colorectal cancer using FIT OC-Sensor Diana. All participants from both groups receive an invitation kit though the post. This includes a consent form for them to sign and a leaflet describing the study. They are asked to store their stool sample at 4°C and send it back to the laboratory using the pre-paid envelope provided. The analyses are performed by experienced laboratory medicine professionals. Participants found to have hidden blood in their stool undergo a colonoscopy (a procedure where a camera is used to look at the inside of the bowel).

| 2413546 | ecrin-mdr-crc

Analysis of 22G siRNA triggered siRNA amplification in Caenorhabditis elegans

Project description:To determine if an endogenous 22G siRNA sensor transgene is subject to siRNA amplification, small RNAs were deep sequenced from the sensor and from a control transgene that is identical to the sensor but lacks an siRNA target site.

2011-12-10 | GSE34320 | GEO

Sample multiplexed scRNA-seq using Nanocoding method for sample barcode labeling

Project description:Sample multiplexed scRNA-seq is a promising strategy to overcome current barriers in high cost and potential technical variations by multiple scRNA-seq tests. In this study, we developed a highly efficienct novel sample barcode labeling method using DNA-encoded Lipid Nanoparticles ('Nanocoding') that could label cells with minimal dependence on their type or sample conditions. This method provids a roubust and general protocol for sample barcoding and multiplexing in scRNA-seq. We demonstrated the performance of Nanocoding through three scRNA-seq studies, which include: 1. mouse spleen cells mix (one dataset including 6 mouse spleen tissues samples); 2. HeLa-mouse Stromal Vascular Fraction(SVF) cells mix (one dataset containing mixed HeLa cell and SVF cell); 3. Aged-Young SVF cells mix (one dataset containing two SVF samples) tests. These studies showcased the biomodal distribution of barcode counts in different models with high signal-to-background ratio, as well as pan-cell labeling activity for efficient and accurate sample-multiplexing. By using Nanocoding, we profiled obsity and age related change in lipid metabolism associated genes or inflammatory related features, in various cell types from spleen or adipose tissues.

2024-12-09 | GSE280262 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data